Repeats [Study As­sess­ment]

posted by ElMaestro  – Denmark, 2013-07-27 14:27 (4307 d 16:11 ago) – Posting: # 11072
Views: 20,719

Hi Sam,

❝ One last suggestions I need from your end, if we go to repeat the whole study without any solid reason except the unexpected PE compared to the pilot study. What will be regulatory queries consequence with the regulatory approval. Will they approve our products based on the new data if it qualifies after repeat.


I don't know how they will react. If you have a PE of 0.79 in one pivotal trial and the next trial passes with flying colors and PE close to 1.00 then I think an eyebrow might be raised here and there.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
117 visitors (0 registered, 117 guests [including 78 identified bots]).
Forum time: 06:38 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5